LONDON (Alliance News) - 4d Pharma PLC on Tuesday said it has received good early results from trials being conducted using its Blautix treatment for irritable bowel syndrome.
The company started the phase 1 trials of Blautix in August last year and it has now received results on the safety and tolerability of the drug in volunteers who have received multiple doses.
4d said the results show Blautix appears to be well-tolerated by the patients involved and the additional data it has received appears to support the drug's pharmacological hypothesis.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
